January 30, 2026
Headlines

LENZ Therapeutics’ Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

01 mins

LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News